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The Leydig tumor cell line, MA-10, expresses the luteinizing hormone receptor, a G protein-coupled
receptor that, when activated with luteinizing hormone or chorionic gonadotropin (CG), stimulates cAMP
production and subsequent steroidogenesis, notably progesterone. These cells also respond to epidermal
growth factor (EGF) and phorbol esters with increased steroid biosynthesis. In order to probe the in-
tracellular pathways along with heterologous receptor down-regulation and cellular desensitization,
cells were preincubated with EGF or phorbol esters and then challenged with CG, EGF, dibutryl-cyclic
AMP, and a phorbol ester. Relative receptor numbers, steroid biosynthesis, and expression of the early
response genes, JUNB and c-FOS, were measured. It was found that in all cases but one receptor down-
regulation and decreased progesterone production were closely coupled under the conditions used; the
exception involved preincubation of the cells with EGF followed by addition of CG where the CG-
mediated stimulation of steroidogenesis was considerably lower than the level of receptor down-reg-
ulation. In a number of instances JUNB and c-FOS expression paralleled the decreases in receptor number
and progesterone production, while in some cases these early response genes were affected little if at all
by the changes in receptor number. This ﬁnding may indicate that even low levels of activated signaling
kinases, e.g. protein kinase A, protein kinase C, or receptor tyrosine kinase, may sufﬁce to yield good
expression of JUNB and c-FOS, or it may suggest alternative pathways for regulating expression of these
two early response genes.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Studies on homologous and heterologous receptor down-reg-
ulation and cellular desensitization have provided considerable
information on cell regulation by exogenous ligands. The mouseB.V. This is an open access article u
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cetate (active phorbol ester)Leydig tumor cell line, MA-10, is responsive to human chorionic
gonadotropin (hCG) via the cell surface luteinizing hormone/
chorionic gonadotropin G protein-coupled receptor (LHR), result-
ing in the stimulation of progesterone biosynthesis [1]. In the ca-
nonical pathway, the hCG-LHR complex leads to activation of
protein kinase A (PKA) and increased intracellular cAMP, resulting
in steroidogenesis [2]. Acting via the cell surface epidermal growth
factor (EGF) tyrosine kinase receptor (EGFR), EGF also activates
steroidogenesis, but at a much lower level than that observed with
hCG [3]. Phorbol esters, intracellular activators of protein kinase C
(PKC), increase steroidogenesis as well [4,5], but, as with EGF, the
stimulation is much less than that achieved with hCG.
Ascoli and colleagues showed a number of years ago that the
three cell stimuli, hCG, EGF, and phorbol esters, reduced the
number of LHRs, and thus responsiveness to hCG-mediated ster-
oidogenesis, by reducing the level of LHR mRNA [6,7], in particular
by decreasing transcription of the LHR gene [8]. Other reports
demonstrated that, following homologous LHR down-regulationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to a depletion of cholesterol [10].
Not surprisingly, there is cross-talk between these three sig-
naling pathways in MA-10 cells. For example, EGF reduces hCG-
responsive cAMP accumulation by inhibiting adenylyl cyclase ac-
tivity [11,12], and hCG-mediated LHR activation has been shown to
lead to the phosphorylation of EGFR and extracellular signal
regulated kinases (Erk1/2) [13] via two independent pathways, an
intracellular one mediated by PKA and an extracellular mediated
by Fyn [14]. EGF, in turn, was shown to attenuate hCG-mediated
cAMP synthesis by inhibiting adenylyl cyclase activity [3,11].
Various signaling pathways lead to the induction of the FOS or
JUN family of proteins, homodimers or heterodimers that form the
activator protein 1 (AP-1) transcription factor complex [15–17].
Genes encoding these proto-oncogenes and other transcription
factors are referred to as early response genes (ERGs), also known
as primary response genes or immediate early genes. Results with
MA-10 cells from our lab [18,19] and from others [20,21] demon-
strated that hCG induced several ERG mRNAs, including c-FOS,
FOSB, c-JUN, JUNB, JUND, as well as c-MYC. Also, other ligands, e.g.
endothelin-1 [22] and tumor necrosis factor-α [23], were found to
increase the mRNAs of several ERGs in MA-10 cells. In addition to
extracellular ligands, it was further shown that phorbol esters
increased the protein levels of certain ERGs [5,24]. Complementing
these studies on Leydig tumor cells, others have reported that
non-transformed Leydig cells, not surprisingly, also respond both
in vitro and in vivo to hCG with increased gene expression of
several ERGs [25–27].
These investigations have provided a solid framework for ex-
tended studies on heterologous receptor down-regulation and
cellular desensitization, with a particular focus on the LHR-protein
kinase A (PKA) axis. In the present study cells were pretreated
with EGF and with the phorbol ester, 12-O-tetradecanoyl-phorbol-
13 acetate (TPA), followed by a challenge of the LHR-PKA axis with
hCG and with dibutryl-cAMP (db-cAMP). This paradigm permits
an evaluation of the effects of signaling cross-talk, heterologous
receptor down-regulation, and cellular desensitization with EGF
(and the resulting receptor tyrosine kinase pathway) and with PKC
(as mediated by the PKC-1,4,5-inositol trisphosphate (IP3)/1,2-
diacylglycerol/calcium pathway) on subsequent hCG/cAMP-medi-
ated actions. In addition to assessing the cellular responses to hCG
and cAMP following EGF and TPA pretreatment, the responses to a
re-challenge with EGF and TPA were also evaluated. The goal of
this work is to gain a better understanding of how the two dif-
ferentiated functions of MA-10 cells, steroidogenesis and ERG ex-
pression, are coupled.2. Materials and methods
2.1. Supplies
Sources of the supplies are given in the Supplement.
2.2. Cell culture
MA-10 cells, kindly provided by Dr. Mario Ascoli (University of
Iowa, Iowa City, IA), were grown in Waymouth’s 752/1 medium,
without phenol red, supplemented with 15% horse serum, 25 mM
Hepes, and 50 μg/mL gentamicin at 37 °C in humidiﬁed air con-
taining 5% CO2 as recommended [1] and described elsewhere [18].
The cells were plated and grown as follows for the various ex-
periments. For the progesterone assays, 1.5105 cells/well in 12-
well tissue culture plates, each well containing 2 mL medium; for
receptor binding assays, 5105 cells/well in 6-well tissue culture
plates, each well containing 3 mL medium; and for RNApreparations 4106 cells/well in T175 ﬂasks, each ﬂask containing
35 mL medium. The serum-containing mediumwas changed every
other day until the cells reached 70% conﬂuency. On the day before
the experiment, the serum-supplemented medium was removed
and replaced with Waymouth’s medium containing 1 mg/mL bo-
vine serum albumin (BSA) with or without one of the factors given
below. On the day of the experiment, the cells received just buffer
(control), 40 ng/mL hCG, 50 ng/mL EGF, 20 ng/mL TPA, 20 ng/mL
4α-phorbol 12,13-didecanoate (4α-PE), or 2 mM db-cAMP plus
1 mM isobutylmethylxanthine (IBMX). Unless stated otherwise,
the experiments were terminated at 0 (control), 15, 30, 45, 60, and
240 min.
2.3. Measurement of secreted progesterone
The medium was removed from control or pre-treated cells
(16 h incubation with 40 ng/mL hCG, 2 mM db-cAMP-plus-1 mM
IBMX, 50 ng/mL EGF, 20 ng/mL TPA, or 20 ng/mL 4α-PE) on the day
of the experiment, followed by washing the cells and then addi-
tion of medium alone or one of the above at the same con-
centration, and then incubated for 4 h at 37 °C. The progesterone
concentration in the medium was determined via a standard
radioimmunoassay using [1,2,6,7-3H] progesterone and rabbit
anti-progesterone. Each experiment was performed independently
in triplicate (with excellent reproducibility), and the results are
presented as mean7SEM for a representative experiment. An
unpaired Student's t-test was used to determine statistical
signiﬁcance.
2.4. Measurement of hCG and EGF binding
Cells were treated as above, and on the day of the experiment
the medium was removed and replaced with medium containing
either 0.3 ng/mL [125I]hCG or [125I]EGF, and then incubated for 2 h
at 37 °C. Nonspeciﬁc binding was measured in the presence of a
200-fold excess of unlabeled ligand. After incubation, the medium
was removed and the cells washed twice with phosphate-buffered
saline, then trypsinized and counted in a γ-counter (LKB Instru-
ments, Inc., Rockville, MD). Each experiment was performed in-
dependently two (hCG) or three (EGF) times demonstrating re-
producibility. The data, normalized to 100% binding in control
cells, are given as mean7SEM for a typical experiment (n¼3), and
statistical signiﬁcance was determined using an unpaired Stu-
dent’s t-test. With the reasonable assumption that the Kd does not
change for either ligand, this paradigm provides a good relative
estimate of the number of available receptors for binding ligand
when comparing different conditions and time points.
2.5. Northern blots of selected ERGs
Cells were incubated with 40 ng/mL hCG, 2 mM db-cAMP-plus-
1 mM IBMX, 20 ng/mL TPA, or 50 ng/mL EGF for 0, 15, 30, 45, 60,
and 240 min followed by Northern analysis. In other experiments,
cells were incubated for 16 h (overnight) with either hCG, TPA, or
EGF at the concentration given above, then washed, and incubated
again with one of the agents, again at the same concentration
denoted above. To isolate total cellular RNA, the classical guanidine
isothiocyanate method [28] was used with modiﬁcations as de-
scribed [18]. At the end of each experiment, the medium was re-
moved and the cells washed with ice-cold phosphate-buffered
saline. Then 7 mL of 4 M guanidine isothiocyanate/40% CsCl was
added to the ﬂasks with DNA being sheared by passing the solu-
tion through an 18-gauge needle 12 . A detailed description of
the method is provided in the Supplement, along with the tech-
niques used for transfer and hybridization. Quantitation of the
blots was via densitometric scanning, and the data are presented
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mRNA (not affected by the treatments used) as an internal stan-
dard. Since the control values were often very low and difﬁcult to
measure with high precision, occasionally requiring over-exposure
of the blots to estimate the basal level, the absolute values of the
fold-increases are subject to error; however, the inherent error is
constant for a given time course. Thus, the fold-increases in mRNA
levels should, in general, be considered more qualitative than
quantitative. Unless noted otherwise each experiment was per-
formed independently twice, and the results are presented as
mean7range.3. Results
3.1. Stimulation of steroidogenesis and ERG expression
To establish appropriate baselines, cellular responses of pro-
gesterone and selected ERG mRNAs, JUNB, c-FOS, and c-JUN, to
hCG, db-cAMP, TPA, and EGF were determined. Progesterone
synthesis increased with each of the two extracellular ligands, hCG
and EGF, and with each of the two intracellular activators, db-
cAMP and TPA (Table 1A). Steroid synthesis was much greater in
cells incubated with hCG or db-cAMP than in those treated with
TPA or EGF.
A few representative Northern blots are given in Supplement
Fig. 1, and the results of densitometric scans showing the relative
temporal expressions of JUNB and c-FOS in response to hCG, db-
cAMP, TPA, and EGF are shown in Fig. 1. Expression of these two
ERGs was low in the basal state and increased signiﬁcantly after
incubation with each of the above factors. There are, however,
interesting temporal differences in the responses of JUNB and c-
FOS to hCG, db-cAMP, TPA, and EGF. For example, in response to
hCG the expression of JUNB increases at 15 min and reaches a
maximum at 30–45 min, and then begins decreasing, returning to
the basal level at 240 min. With db-cAMP, JUNB expression beginsTable 1
Progesterone synthesis by MA-10 cells in response to hCG, db-cAMP, 4α-PE, TPA, and EG
subsequent stimulation with hCG, db-cAMP, and either TPA or EGF.a
A. Overnight incubation in medium only followed by incubation with hCG, db-cAMP,
Treatment Control hCG db-cAMP
Prog. (ng/mL) 0.770.1 46.773.3 43.976
Percentage 0 100 94
B. Overnight incubation with 4α-PE and subsequent incubation with hCG, db-cAMP, a
Treatment Control hCG db-cAMP
Prog. (ng/mL) 0.770.1 52.175.9 52.175.
Percentage 0 112 119
C. Overnight incubation with TPA and subsequent with hCG, db-cAMP, and EGF
Treatment Control hCG db-cAMP
Prog. (ng/mL) 0.870.1 8.570.1b 10.071.
Percentage 0 17 21
D. Overnight incubation with EGF and subsequent incubation with hCG, db-cAMP, an
Treatment Control hCG db-cAMP
Prog. (ng/mL) 1.370.1 37.9710.6 47.878.
Percentage 0 80 108
a Accumulated medium progesterone (Prog.) was measured 4 h after addition of sti
progesterone concentration in the medium with overnight incubation in medium fol
percentages refer to the respective values in panel A. For example, the progesterone conc
A; likewise for db-cAMP in panels B, C, and D compared to that of db-cAMP in panel A; al
D with that of TPA in panel A; and The various percentages were determined as follow
respective control concentration)/(progesterone concentration of the stimulus in panel
b Po0.0001.
c Po0.01.at about 30 min and increases gradually, reaching a maximum at
60 min (or later) and also declines to the basal level by 240 min.
TPA leads to a gradual time-dependent increase in JUNB expres-
sion up to at least 60 min, after which the expression is just above
the basal level at 240 min. Incubation with EGF results in in-
creasing fold-expression of JUNB up to 30 min, where it remains
elevated for another 30 min and by 240 min is slightly above basal
levels. The kinetics with c-FOS, on the other hand, exhibit maxima
at 30 min for hCG and EGF, at 45 min for TPA, and at 60 min or
later for db-cAMP. The increase in c-JUN mRNA was modest in
response to these cellular stimuli, e.g. 2–6-fold, and for this reason
the results with c-JUN are not shown for subsequent experiments.
3.2. The inactive phorbol ester
As shown in Table 1A, 4α-PE is not steroidogenic; moreover,
preincubation of MA-10 cells with the inactive phorbol ester had
no appreciable effect on subsequent stimulation of progesterone
synthesis by hCG, db-cAMP, or EGF (Table 1B). Radioreceptor as-
says demonstrated that preincubation of the cells with 4α-PE had
no signiﬁcant effect on the apparent number of hCG and EGF re-
ceptors (Table 2). Thus, the effects of TPA are speciﬁc for the active
compound.
3.3. Effects of pretreatment with TPA
Overnight incubation of MA-10 cells with TPA led to a reduc-
tion of over 40% in the binding of [125I]hCG (Table 2). This result is
in reasonable agreement with the report by Wang et al. [7] in
which hCG binding was determined over a 48 h time course in the
presence of PMA; after 16 h the reduction in binding was about
20–30%. Whereas hCG binding was reduced 40–45% by TPA, hCG-
mediated steroidogenesis was diminished by more than 80%
(Table 1C). In addition to heterologous LHR down-regulation, these
results are strongly indicative of cellular desensitization. Of com-
parative interest with hCG, there was also a signiﬁcant reductionF (A) and following overnight incubation with 4α-PE (B), TPA (C), and EGF (D) with
TPA, 4α-PE, and EGF
4α-PE TPA EGF
.3 0.870.1b 10.671.0b 4.870.5b
0.2 22 9
nd EGF
EGF
9 4.670.3
95
EGF
3c 2.470.2c
39
d TPA
TPA
6 5.770.3c
44
mulus. In panel A the percentages shown in parentheses refer to the accumulated
lowed by addition of hCG as the base value, i.e. 100%. In panels B, C, and D the
entrations elicited by hCG in panels B, C, and D are compared to that of hCG in panel
so for EGF in panels B and C compared to that of EGF in panel A; and for TPA in panel
s from the values in ng/mL: [(progesterone concentration produced by stimulus-
A – respective control concentration)]100%.
Fig. 1. Temporal expression of JUNB and c-FOSmRNAs in MA-10 cells. Responses to hCG (40 ng/mL), db-cAMP (2 mM-plus-1 mM IBMX), TPA (20 ng/mL), and EGF (50 ng/mL)
are shown, and the data are presented as fold-increase over control (0 min). Each point represents the mean7range of integrated intensities from two independent
experiments.
T.-M. Chen et al. / Biochemistry and Biophysics Reports 5 (2016) 305–312308of progesterone production (also ca. 80%) in the cellular response
to db-cAMP in TPA-treated cells (Table 1C).
[125I]EGF binding to cells preincubated with TPA was reduced
some 65% (Table 2), and progesterone synthesis was also dimin-
ished about 60% as well (Table 1C). These ﬁndings indicate that
under these conditions receptor number and steroidogenic re-
sponsiveness are closely coupled. One caveat, however, is that the
relatively low levels of EGF-mediated progesterone synthesis
preclude high accuracy.
Desensitization with TPA followed by a challenge with hCG,cAMP, and EGF (Fig. 2) resulted in some interesting similarities and
differences compared to the results in Fig. 1. hCG-mediated ex-
pression of JUNB was similar to that of cells that had not been
previously incubated with TPA, except that expression remained
elevated for 60 and 240 min. The temporal responses of JUNB ex-
pression to db-cAMP and EGF were similar to those presented in
Fig. 1 except that the EGF response seemed blunted. The fold-ac-
tivation of c-FOS following prior incubation with TPA was similar
to that given in Fig. 1 following incubation with hCG and db-cAMP;
with EGF the response appears somewhat blunted and the fold-
Table 2
Radioreceptor assays following incubation of MA-10 cells with either. medium only
or medium containing 4α-PE, TPA, or EGF.a
Overnight incubation [125I]hCG binding (%) [125I]EGF binding (%)
Medium 100 100
4α-PE 94.970.6 98.474.4
TPA 57.373.3b 34.471.3b
EGF 69.573.5b 4.570.9b
a Control cells were incubated overnight in medium only followed by mea-
surements of speciﬁc binding with radiolabeled hCG and EGF as described in Ma-
terials and Methods. All results are expressed as % speciﬁc binding relative to
control.
b Po0.0001.
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liminary results indicated that challenging TPA-pretreated cells
with TPA yielded greatly reduced levels of both JUNB and c-FOS
(data not shown).
3.4. Effects of pretreatment with EGF
Measurement of bound [125I]EGF to MA-10 cells that had been
incubated overnight with a saturating concentration of unlabeled
EGF indicated a 95% reduction in EGFR (Table 2). Thus, under theFig. 2. Temporal expression of JUNB and c-FOS mRNAs. The MA-10 cells were incubated
db-cAMP (2 mM-plus-1 mM IBMX), and EGF (50 ng/mL). See Fig. 1 legend for further dconditions used, EGFR down-regulation was achieved. [125I]hCG
binding to these EGF-pretreated cells suggested a 30% reduction in
LHR (Table 2), in reasonable agreement with the reports by Ascoli
and colleagues [6,7,29], who also showed that after 24–48 h in-
cubation with EGF, hCG binding was reduced some 80%. Consistent
with our binding data, addition of hCG to the EGF-treated cells led
to a 20% reduction in progesterone synthesis compared to that of
untreated cells (Table 1D). As also presented in Table 1D, addition
of db-cAMP produced essentially the same amount of progester-
one in the EGF-treated and control cells, while the TPA response
was about 55% less following EGF pretreatment. These results on
hCG and db-cAMP are, by and large, in qualitative agreement with
earlier studies in which it was reported that following 48 h of
preincubation with EGF, hCG-mediated progesterone synthesis
was reduced about 90% while 8-Bromo-cAMP-mediated proges-
terone synthesis was some 108% of that in the absence of EGF
pretreatment [6].
Pretreatment of the cells with EGF followed by a challenge with
either hCG or TPA resulted in, if anything, a small increase in JUNB
expression and no signiﬁcant change in c-FOS expression with hCG
(relative to that produced by hCG without a preincubation), and no
change in expression of either JUNB or c-FOS expression in re-
sponse to TPA (Fig. 3). As also shown in Fig. 3, incubation of MA-10
cells with fresh EGF, following preincubation with EGF, resulted inovernight with TPA (20 ng/mL), then washed and incubated with hCG (40 ng/mL),
etails.
Fig. 3. Temporal expression of JUNB and c-FOS mRNAs. The MA-10 cells were incubated overnight with EGF (50 ng/mL), then washed and incubated with hCG (40 ng/mL),
TPA (20 ng/mL), and EGF (50 ng/mL). See Fig. 1 legend for further details; the only exception is that the data for c-FOS in the EGF/TPA panel represents a single measurement
at each time point. Note the low ordinate values in the EGF/EGF panels compared to the others.
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gested that c-FOS expression was also signiﬁcantly diminished.4. Discussion
The ﬁndings reported herein have shown that steroidogenesis
and expression of JUNB and c-FOS in MA-10 cells can be stimulated
not only by hCG and db-cAMP, but also by TPA and EGF, albeit at
much lower levels. Although some portions of this work have been
reported by others, this is the ﬁrst report in which steroidogenesis
and ERG expression have been determined under the same con-
ditions. Ascoli et al. [3] originally showed that EGF was steroido-
genic for these cells, although they reported a lower increase in
progesterone production compared to hCG than that found herein.
Interestingly, Jo et al. [30] reported that phorbol-12-myristate 13-
acetate (PMA) failed to activate steroidogenesis unless supple-
mented with a low concentration of db-cAMP, although increased
progesterone production in response to PMA, with no added db-
cAMP, was found earlier [4].Our ﬁndings are in agreement with those of Wang et al. [7]
who also found that overnight incubation of the cells with TPA and
with EGF reduced the number of LHRs and EGFRs. Preincubation of
cells with TPA diminished the ability of hCG, db-cAMP, and EGF to
stimulate steroid production, while preincubation with EGF also
reduced steroid synthesis by hCG and TPA, but not db-cAMP. In-
terestingly, the degree of EGF-mediated down-regulation of LHR
(ca. 30%) roughly corresponds to the reduction in the degree of
hCG-mediated steroidogenesis in these cells (ca. 20%), and the
degree of TPA-mediated down-regulation of EGFR (about 65%)
correlates with the reduction in the ability of EGF to stimulate
steroidogenesis (ca. 60%). These results, collected under the de-
ﬁned experimental conditions, suggest a correlation between re-
ceptor number and steroidogenesis. An exception is TPA-mediated
down-regulation of LHR (ca. 40–45%) and the reduction in the
amount of steroidogenesis elicited by hCG in these pretreated cells
(about 80–85%). In this case the decrease in steroidogenesis ex-
ceeds that expected from receptor number alone, indicating both
receptor down-regulation and cellular desensitization.
The ERG expression data agree, at least qualitatively, with other
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different conditions and methods of collecting/reporting the data,
e.g. showing blots only or using immunoblots of protein, prevent a
detailed comparison. Others also reported a minimal effect of
cAMP on c-JUN mRNA [23] and a 2–4-fold increase in c-JUN pro-
tein elicited by PMA [5,24]; in contrast, Suzuki et al. [20] found a
time-dependent hCG-mediated increase in c-JUN. We have no
explanation for these disparate results. Of the receptor down-
regulation and cellular desensitization protocols used, the most
dramatic change in ERG expression was the large decrease in both
JUNB and c-FOS expression following EGFR down-regulation by
EGF with a subsequent challenge with EGF. In a similar vein,
preliminary data suggest that desensitization with TPA followed
by a TPA challenge led to major reductions in JUNB and c-FOS
expression (data not shown).
The results presented herein show that while receptor down-
regulation and desensitization of ERG expression generally corre-
late quantitatively, in certain circumstances this is not the case.
Supplement Table 1 shows a summary of the results on receptor
number, steroid production, and ERG expression. In a number of
instances following preincubation with either TPA or EGF and a
subsequent challenge with hCG, db-cAMP, TPA, or EGF, there is a
correlation between receptor number, steroid production, and
JUNB/c-FOS expression. In other cases ERG expression may not
change dramatically while receptor number and progesterone
production diminish. These results may suggest that low levels of
activated signaling intermediates such as protein kinase A, protein
kinase C, or tyrosine kinase may sufﬁce to yield good expression of
JUNB and c-FOS; it may also indicate alternative pathways for
regulating expression of these two early response genes. Our re-
sults do not permit a distinction between the two possibilities.
Also, we have no information on the cAMP response element
binding protein (CREB) and the CREB binding protein in these
paradigms. CREB can be phosphorylated not only by PKA but also
by PKC [31], representing another level of cross-talk of the in-
tracellular signaling pathways.
Recent studies on the transcriptome of SKOV-3 human ovarian
cancer cells stably expressing LHR showed that luteinizing hor-
mone-mediated activation of LHR resulted in only a modest up-
regulation of JUNB (1.2-fold) and c-FOS (3.0-fold) in 60 min [32],
fold-activations less than that observed herein with MA-10 Leydig
tumor cells. Moreover, a comparison of the different gonado-
tropin-mediated fold-activations of ERGs in rat Leydig cells [25,27]
and pig Leydig cells [26] suggests species differences, although this
must be tempered by the differences reported using a single cell
type, the MA-10 Leydig tumor line [5,18,19,20,21]. qRT-PCR would
probably resolve at least some of the issues; however, even in a
single species cancer cells exhibit a shift in the dimer composition
of AP-1 [33] and hence differences in ERG expression can be ex-
pected between non-transformed and transformed cells from the
same species. Thus, ERG expression in response to LHR activation
is, not surprisingly, cell/species speciﬁc.
Interactions of the PKA pathway with other signaling systems
are well documented [34], including the potential action(s) of
cAMP independent of PKA, e.g. via the exchange protein directly
activated by cAMP (EPAC) [35]. Also, in addition to the phos-
phorylation of CREB as mentioned above, PKC signaling can impact
on PKA-mediated actions via the receptor for activated C kinase 1
(RACK1), a scaffold protein for PKC and the cAMP-speciﬁc phos-
phodiesterase, PDE4D5 [36]. Interestingly, one isoform of PKC ac-
tivates PDE4D5 when it is bound to RACK1, thus reducing cellular
cAMP. The roles of EPAC and RACK1 in MA-10 cells have not, to the
best of our knowledge, been explored.5. Conclusions
The MA-10 cells are an attractive tumor cell line in that one of
the differentiated functions of the cells, namely steroidogenesis,
can be investigated using multiple signaling pathways: PKA, PKC,
and tyrosine kinase. The present study has demonstrated that
activation of these three pathways by hCG, TPA, and EGF, respec-
tively, leads to increases in both progesterone biosynthesis and
JUNB and c-FOS expression. Heterologous receptor down-regula-
tion and cellular desensitization, followed by challenges with hCG,
db-cAMP, TPA, and EGF indicate that, under the experimental
conditions used, there is a close parallel between receptor number
and steroidogenesis in most cases investigated. An exception is
that of preincubation with TPA followed by challenge of the cells
with hCG, in which case progesterone production is greater than
that expected from the loss of receptors alone. Expression of JUNB
and c-FOS often, but not always, paralleled the decreases in re-
ceptor number and steroidogenesis. Thus, low levels of in-
tracellular second messengers and kinases activated may sufﬁce to
render responses comparable to those achieved in the absence of
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